Sillajen Biotherapeutics (215600):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Sillajen Biotherapeutics (215600) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8279)・商品コード:DATA904C8279
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:24
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Sillajen Biotherapeutics (SillaJen), formerly SillaJen Inc, is a biotechnology company that designs and develops oncolytic immunotherapeutics for the treatment of cancer. The company’s pipeline products comprise Pexa-Vec, an oncolytic immunotherapeutic virus which is in Phase III trial that is used for the treatment of primary liver cancer. It also develops JX929, a chemosensitizing oncolytic immunotherapy that eradicates cancer; activates chemotherapy in cancer tissue; administers as a monotherapy to patients with breast, colorectal, and pancreatic cancer; and treats melanoma and metastatic colon cancer. The company operates in South Korea and the US. Sillajen is headquartered in Busan, South Korea.

Sillajen Biotherapeutics (215600) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deal Details 10
Private Equity 10
Medivate Partners Invests in SillaJen 10
Partnerships 11
SillaJen Enters into R&D Agreement with National Cancer Institute 11
Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 12
Transgene Amends Agreement With SillaJen 13
Equity Offering 14
SillaJen Plans to Raise Funds in IPO 14
Debt Offering 15
SillaJen Plans to Raise up to USD42 Million in Private Placement of Bonds 15
Acquisition 16
SillaJen Completes Acquisition Of Jennerex For US$150 Million 16
SillaJen Acquires Hibiscus Biotherapeutics 18
Sillajen Biotherapeutics – Key Competitors 19
Sillajen Biotherapeutics – Key Employees 20
Sillajen Biotherapeutics – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Product News 22
04/12/2017: Transgene and Institut Bergonie Start the Phase 2 Part of the METROmaJX Trial 22
Clinical Trials 23
Apr 24, 2017: SillaJen And Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial For Pexa-Vec in Advanced Liver Cancer 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sillajen Biotherapeutics, Deals By Therapy Area, 2012 to YTD 2018 8
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Medivate Partners Invests in SillaJen 10
SillaJen Enters into R&D Agreement with National Cancer Institute 11
Regeneron Pharma and SillaJen Biotherapeutics Enter into Agreement 12
Transgene Amends Agreement With SillaJen 13
SillaJen Plans to Raise Funds in IPO 14
SillaJen Plans to Raise up to USD42 Million in Private Placement of Bonds 15
SillaJen Completes Acquisition Of Jennerex For US$150 Million 16
SillaJen Acquires Hibiscus Biotherapeutics 18
Sillajen Biotherapeutics, Key Competitors 19
Sillajen Biotherapeutics, Key Employees 20
Sillajen Biotherapeutics, Other Locations 21
Sillajen Biotherapeutics, Subsidiaries 21

List of Figures
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sillajen Biotherapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Sillajen Biotherapeutics (215600):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8279)販売に関する免責事項を必ずご確認ください。
★調査レポート[Sillajen Biotherapeutics (215600):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆